Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
1997 pubmed

Effects of muscarinic and adrenergic blockade on growth hormone secretion induced by growth hormone-releasing peptide-2 (GHRP-2) in ovariectomized ewes.

Roh. S G SG; Hirota. M M; He. M L ML; Matsunaga. N N; Hidaka. S S; Hidari. H H

Key Findings

  • Error

Practical Outcomes

  • Error

Summary

Error: Timeout.

Abstract

This study was performed to investigate whether the blockade of cholinergic muscarinic and adrenergic pathways was involved in the GH-releasing effect of GH-releasing peptide-2 (GHRP-2) in ovariectomized ewes. Cholinergic muscarinic antagonist, atropine (0.2 mg/kg, i.v., 15 min before GHRP-2 administration) blunted the GH secretion caused by GHRP-2 (12.5 microg/kgBW). alpha-Adrenergic antagonist phentolamine (15 microg/kgBW x min, infusion from -15 to 30 min) did not affect the GH response to GHRP-2, and beta-adrenergic antagonist propranolol (0.25 mg/kgBW, i.v., 15 min before GHRP-2 administration) did not suppress the GHRP-2-induced GH release. These results showed that cholinergic muscarinic antagonist agent, atropine, exerts an inhibitory effect on GHRP-2-induced GH secretion in ovariectomized ewes.

Study Information

Provider

pubmed

Year

1997

DOI

10.1507/endocrj.44.861